| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SF; MGF; SCF; SLF; DCUA; FPH2; FPHH; KL-1; Kitl; SHEP7; DFNA69 |
| Entrez GeneID | 4254 |
| clone | 2E1F9 |
| WB Predicted band size | 30.9kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human KITLG (AA: Extra(26-214)) expressed in Mammalian |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与KITLG抗体相关的参考文献示例(文献信息为虚拟模拟，仅供格式参考)：
---
1. **文献名称**：*Targeting KITLG Signaling with a Monoclonal Antibody Inhibits Melanoma Progression*
**作者**：Zhang Y, et al.
**摘要**：本研究开发了一种靶向KITLG的单克隆抗体，通过阻断其与受体c-KIT的相互作用，抑制黑色素瘤细胞的迁移和侵袭。体内实验表明，该抗体可显著减少肿瘤转移，为KITLG通路在癌症治疗中的应用提供依据。
---
2. **文献名称**：*Anti-KITLG Antibody Enhances Hematopoietic Stem Cell Mobilization in Mice*
**作者**：Smith JL, et al.
**摘要**：文章报道了一种新型抗KITLG抗体在小鼠模型中促进造血干细胞动员的效果。该抗体通过竞争性抑制KITLG/c-KIT结合，增加外周血中干细胞数量，为临床干细胞移植提供了潜在策略。
---
3. **文献名称**：*Structural Characterization of a Humanized Anti-KITLG Antibody for Autoimmune Disease Therapy*
**作者**：Tanaka M, et al.
**摘要**：研究团队解析了一种人源化抗KITLG抗体的晶体结构，证明其可有效中和KITLG介导的炎症反应。动物实验显示，该抗体能缓解类风湿性关节炎模型的症状，提示其治疗自身免疫疾病的潜力。
---
如需真实文献，建议通过PubMed或Google Scholar搜索关键词(如 *KITLG antibody therapeutic* 或 *anti-SCF neutralizing antibody*)获取最新研究。
**Background of KITLG Antibody**
The KIT ligand (KITLG), also known as stem cell factor (SCF) or steel factor, is a cytokine critical for cellular signaling via its receptor c-KIT, a tyrosine kinase. It plays essential roles in hematopoiesis, germ cell development, melanogenesis, and mast cell regulation by activating downstream pathways like PI3K/AKT and MAPK/ERK, which govern survival, proliferation, and differentiation. Dysregulation of KITLG/c-KIT signaling is linked to cancers (e.g., gastrointestinal stromal tumors, leukemia), inflammation, and infertility.
KITLG antibodies are tools or therapeutics designed to target this pathway. In research, they block KITLG-c-KIT interactions to study physiological/pathological mechanisms. Therapeutically, monoclonal antibodies (mAbs) inhibit aberrant c-KIT signaling in cancers, suppressing tumor growth. They also show potential in managing allergies and autoimmune disorders by modulating mast cell activity. Polyclonal antibodies are often used in diagnostics to detect KITLG expression levels, aiding disease biomarker studies. Challenges include minimizing off-target effects and overcoming drug resistance. Ongoing research focuses on optimizing antibody specificity and efficacy for clinical applications.
×
